Neurocrine Biosciences Inc
NASDAQ:NBIX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111.62
153.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Other Current Assets
Neurocrine Biosciences Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Other Current Assets
$121.7m
|
CAGR 3-Years
34%
|
CAGR 5-Years
40%
|
CAGR 10-Years
40%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$3.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$449.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$412m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
Neurocrine Biosciences Inc
Glance View
Neurocrine Biosciences Inc. is a biopharmaceutical company committed to improving the lives of those suffering from neurological and endocrine disorders. Founded in 1992 and based in San Diego, California, Neurocrine has carved out a niche in developing innovative therapies that target complex medical conditions. Its flagship product, Ingrezza (valbenazine), has rapidly gained traction as a leading treatment for tardive dyskinesia, a movement disorder often caused by long-term antipsychotic medication use. This success has propelled the company into the limelight and established it as a key player in the CNS (central nervous system) market. Investors are captivated by Neurocrine’s strong clinical pipeline, promising research partnerships, and an agile operational approach that enable it to adapt swiftly to the evolving landscape of biopharma. The company’s growth story is further enhanced by its commitment to expanding its product portfolio. With therapies in development for conditions such as endometriosis and other hormonal disorders, Neurocrine is not just a one-hit wonder; it is poised to become a powerhouse in the biotech domain. Boasting a robust financial position, the company leverages its research capabilities to identify and bring forward transformative treatments. For investors, Neurocrine represents an opportunity at the intersection of science and compassion, as it continually strives to address unmet medical needs with its innovative solutions. With strong leadership and a dedication to breakthrough therapies, the company stands ready to capitalize on the growing demand for specialized medications within the healthcare landscape.
See Also
What is Neurocrine Biosciences Inc's Other Current Assets?
Other Current Assets
121.7m
USD
Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Other Current Assets amounts to 121.7m USD.
What is Neurocrine Biosciences Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
40%
Over the last year, the Other Current Assets growth was 12%. The average annual Other Current Assets growth rates for Neurocrine Biosciences Inc have been 34% over the past three years , 40% over the past five years , and 40% over the past ten years .
You don't have any saved screeners yet
